Meeting
2021 ASCO Annual Meeting
IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study.
Authors
Valeriy Vladimirovich Breder
N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation
Valeriy Vladimirovich Breder , Arndt Vogel , Philippe Merle , Richard S. Finn , Peter R. Galle , Andrew X. Zhu , Ann-Lii Cheng , Yin-Hsun Feng , Daneng Li , Vincent E. Gaillard , Lindong Li , Alan Nicholas , Riccardo Lencioni
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT03434379
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4073)
DOI
10.1200/JCO.2021.39.15_suppl.4073
Abstract #
4073
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor).
First Author: Michel Ducreux
Poster
2020 ASCO Virtual Scientific Program
Complete responses (CR) in patients receiving atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC).
First Author: Richard S. Finn
Poster
2020 ASCO Virtual Scientific Program
Clinical value of atezolizumab + bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis.
First Author: Arndt Vogel
Poster
2018 ASCO Annual Meeting
IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma.
First Author: Richard S. Finn